Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

96.48USD
19 Oct 2017
Change (% chg)

$0.44 (+0.46%)
Prev Close
$96.04
Open
$95.50
Day's High
$96.60
Day's Low
$94.51
Volume
1,866,427
Avg. Vol
1,680,508
52-wk High
$96.60
52-wk Low
$55.10

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Abbvie and harpoon therapeutics announce immuno-oncology research collaboration

* Abbvie and Harpoon Therapeutics announce immuno-oncology research collaboration

18 Oct 2017

REFILE-UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research

Oct 12 The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer.

12 Oct 2017

BRIEF-AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology

* AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology

10 Oct 2017

Second U.S. jury finds AbbVie misrepresented risks of AndroGel

A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.

06 Oct 2017

UPDATE 1-Second U.S. jury finds AbbVie misrepresented risks of AndroGel

Oct 5 A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.

06 Oct 2017

AbbVie hit with $140 mln verdict in AndroGel trial -lawyer

Oct 5 A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in an emailed statement.

06 Oct 2017

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023

Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday.

28 Sep 2017

BRIEF-Amgen and AbbVie agree to settlement allowing commercialization of Amgevita

* Amgen and AbbVie agree to settlement allowing commercialization of Amgevita

28 Sep 2017

BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c

* Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c

27 Sep 2017

BRIEF-AbbVie announces approval of Maviret for chronic hepatitis C treatment in Japan

* AbbVie announces approval of Maviret (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) in Japan

27 Sep 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.04 +1.36
Pfizer Inc. (PFE.N) $36.24 +0.41
Novartis AG (NOVN.S) CHF84.30 -0.05
Merck & Co., Inc. (MRK.N) $63.75 +0.24
Roche Holding Ltd. (ROG.S) CHF235.70 -2.90
Roche Holding Ltd. (RO.S) CHF238.90 -2.80
Abbott Laboratories (ABT.N) $56.00 +0.23
Eli Lilly and Co (LLY.N) $86.36 +0.63
Sanofi SA (SASY.PA) €84.02 -0.24

Earnings vs. Estimates